Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model-Reference-Cited by-同舟云学术

Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model

Published:2012-01-05 Issue:3 Volume:11 Page:752-762
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Pastuskovas Cinthia V.,Mundo Eduardo E.,Williams Simon P.,Nayak Tapan K.,Ho Jason,Ulufatu Sheila,Clark Suzanna,Ross Sarajane,Cheng Eric,Parsons-Reponte Kathryn,Cain Gary,Van Hoy Marjie,Majidy Nicholas,Bheddah Sheila,dela Cruz Chuh Josefa,Kozak Katherine R.,Lewin-Koh Nicholas,Nauka Peter,Bumbaca Daniela,Sliwkowski Mark,Tibbitts Jay,Theil Frank-Peter,Fielder Paul J.,Khawli Leslie A.,Boswell C. Andrew

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer;International Journal of Molecular Sciences;2024-09-12

2. Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials;Nature Reviews Clinical Oncology;2024-04-10

3. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab;Pathology - Research and Practice;2023-12

4. High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply;JAMA Oncology;2023-05-01

5. Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients;CPT: Pharmacometrics & Systems Pharmacology;2023-02-15